The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | Treating triple refractory CLL in patients with HIV
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, summarizes a case study involving a patient with triple refractory chronic lymphocytic leukemia (CLL). In addition to being refractory to BTK and BCL2 inhibitors, the man was HIV positive. Chimeric antigen receptor (CAR) T-cell therapy is typically offered for patients with relapsed/refractory CLL, but was not possible for the patient as harvesting T cells would be an obstacle. Allogeneic stem cell transplant was consequently determined to be the best course of action. This is interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
